118 related articles for article (PubMed ID: 24457433)
1. CAS P8 -652 6N del polymorphism and breast cancer risk: a systematic review and meta-analysis.
Li Z; Wang J; Wang F; Ma Z; Yu Z
Neth J Med; 2014 Jan; 72(1):10-6. PubMed ID: 24457433
[TBL] [Abstract][Full Text] [Related]
2. Association of two CASP8 polymorphisms with breast cancer risk: a meta-analysis.
Sergentanis TN; Economopoulos KP
Breast Cancer Res Treat; 2010 Feb; 120(1):229-34. PubMed ID: 19629679
[TBL] [Abstract][Full Text] [Related]
3. CASP8 -652 6N del polymorphism and cancer risk: a meta-analysis of 30 case-control studies in 50,112 subjects.
Zhang F; Yang Y; Guo C; Wang Y
Mutagenesis; 2012 Sep; 27(5):559-66. PubMed ID: 22513478
[TBL] [Abstract][Full Text] [Related]
4. CASP8 -652 6N del polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis.
Peng Q; Lao X; Tang W; Chen Z; Li R; Wang J; Deng Y; Li T; Qin X; Li S
PLoS One; 2014; 9(2):e87925. PubMed ID: 24498403
[TBL] [Abstract][Full Text] [Related]
5. Bi-directional PCR allele-specific amplification (bi-PASA) for detection of caspase-8 -652 6N ins/del promoter polymorphism (rs3834129) in breast cancer.
Hashemi M; Eskandari-Nasab E; Fazaeli A; Rezaei H; Mashhadi MA; Arbabi F; Taheri M
Gene; 2012 Aug; 505(1):176-9. PubMed ID: 22659694
[TBL] [Abstract][Full Text] [Related]
6. The relationship of CASP 8 polymorphism and cancer susceptibility: a meta-analysis.
Ji GH; Li M; Cui Y; Wang JF
Cell Mol Biol (Noisy-le-grand); 2014 Dec; 60(6):20-8. PubMed ID: 25553350
[TBL] [Abstract][Full Text] [Related]
7. Impact of caspase-8 (CASP8) -652 6N del and D302H polymorphisms on prostate cancer in different ethnic groups.
Zhang CD; Li HT; Liu K; Lin ZD; Peng QL; Qin X; He M; Wu H; Mo ZN; Yang XL
Asian Pac J Cancer Prev; 2014; 15(18):7713-8. PubMed ID: 25292051
[TBL] [Abstract][Full Text] [Related]
8. The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis.
de Martino M; Haitel A; Schatzl G; Klingler HC; Klatte T
J Urol; 2013 Aug; 190(2):717-22. PubMed ID: 23313206
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of caspase 8 -652 6N InsDel and Asp302His polymorphisms for breast cancer.
Kuhlmann JD; Bankfalvi A; Schmid KW; Callies R; Kimmig R; Wimberger P; Siffert W; Bachmann HS
BMC Cancer; 2016 Aug; 16():618. PubMed ID: 27507139
[TBL] [Abstract][Full Text] [Related]
10. CASP8 promoter polymorphism is associated with high-risk HPV types and abnormal cytology but not with cervical cancer.
Chatterjee K; Williamson AL; Hoffman M; Dandara C
J Med Virol; 2011 Apr; 83(4):630-6. PubMed ID: 21328377
[TBL] [Abstract][Full Text] [Related]
11. The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study.
Frank B; Rigas SH; Bermejo JL; Wiestler M; Wagner K; Hemminki K; Reed MW; Sutter C; Wappenschmidt B; Balasubramanian SP; Meindl A; Kiechle M; Bugert P; Schmutzler RK; Bartram CR; Justenhoven C; Ko YD; Brüning T; Brauch H; Hamann U; Pharoah PP; Dunning AM; Pooley KA; Easton DF; Cox A; Burwinkel B
Breast Cancer Res Treat; 2008 Sep; 111(1):139-44. PubMed ID: 17891485
[TBL] [Abstract][Full Text] [Related]
12. Functional variants in cell death pathway genes and risk of pancreatic cancer.
Yang M; Sun T; Wang L; Yu D; Zhang X; Miao X; Liu J; Zhao D; Li H; Tan W; Lin D
Clin Cancer Res; 2008 May; 14(10):3230-6. PubMed ID: 18483392
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism in HLA-G 3'UTR 14-bp ins/del and risk of cancer: a meta-analysis of case-control study.
Li T; Huang H; Liao D; Ling H; Su B; Cai M
Mol Genet Genomics; 2015 Aug; 290(4):1235-45. PubMed ID: 25573780
[TBL] [Abstract][Full Text] [Related]
14. The six-nucleotide deletion/insertion variant in the CASP8 promoter region is inversely associated with risk of squamous cell carcinoma of the head and neck.
Li C; Lu J; Liu Z; Wang LE; Zhao H; El-Naggar AK; Sturgis EM; Wei Q
Cancer Prev Res (Phila); 2010 Feb; 3(2):246-53. PubMed ID: 20086182
[TBL] [Abstract][Full Text] [Related]
15. CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies.
Yin M; Yan J; Wei S; Wei Q
Carcinogenesis; 2010 May; 31(5):850-7. PubMed ID: 20176653
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of caspase-8 -652 6N del polymorphism and digestive tract cancer risk.
Du H; Song GX; Fang MZ; Shu YQ; Zhao X; Zhu LJ
J Biomed Res; 2019 Jun; 33(3):173-180. PubMed ID: 30057371
[TBL] [Abstract][Full Text] [Related]
17. Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer.
Liamarkopoulos E; Gazouli M; Aravantinos G; Tzanakis N; Theodoropoulos G; Rizos S; Nikiteas N
Gastric Cancer; 2011 Oct; 14(4):317-21. PubMed ID: 21461653
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the CASP8 gene and the risk of epithelial ovarian cancer.
Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
Gynecol Oncol; 2011 Sep; 122(3):554-9. PubMed ID: 21714991
[TBL] [Abstract][Full Text] [Related]
19. Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases.
De Vecchi G; Verderio P; Pizzamiglio S; Manoukian S; Barile M; Fortuzzi S; Ravagnani F; Pierotti MA; Radice P; Peterlongo P
Breast Cancer Res Treat; 2009 Feb; 113(3):607-8. PubMed ID: 18343995
[No Abstract] [Full Text] [Related]
20. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter associated with risk and progression of bladder cancer.
Wang M; Zhang Z; Tian Y; Shao J; Zhang Z
Clin Cancer Res; 2009 Apr; 15(7):2567-72. PubMed ID: 19276244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
